KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Payables: 2009-2025

Historic Payables for Charles River Laboratories International (CRL) over the last 17 years, with Sep 2025 value amounting to $169.6 million.

  • Charles River Laboratories International's Payables rose 24.75% to $169.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $605.1 million, marking a year-over-year increase of 6.59%. This contributed to the annual value of $140.3 million for FY2024, which is 16.93% down from last year.
  • Charles River Laboratories International's Payables amounted to $169.6 million in Q3 2025, which was up 16.34% from $145.8 million recorded in Q2 2025.
  • Over the past 5 years, Charles River Laboratories International's Payables peaked at $226.0 million during Q1 2022, and registered a low of $110.9 million during Q2 2021.
  • Moreover, its 3-year median value for Payables was $140.2 million (2023), whereas its average is $142.7 million.
  • In the last 5 years, Charles River Laboratories International's Payables surged by 90.56% in 2022 and then crashed by 46.90% in 2023.
  • Over the past 5 years, Charles River Laboratories International's Payables (Quarterly) stood at $198.1 million in 2021, then rose by 3.93% to $205.9 million in 2022, then declined by 17.96% to $168.9 million in 2023, then declined by 16.93% to $140.3 million in 2024, then rose by 24.75% to $169.6 million in 2025.
  • Its Payables stands at $169.6 million for Q3 2025, versus $145.8 million for Q2 2025 and $149.3 million for Q1 2025.